RCUS vs EXEL

For growth investors, Exelixis, Inc.

(EXEL) is the stronger pick with 7. 0% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Exelixis, Inc. (EXEL) offers the better valuation at 17. 5x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Arcus Biosciences, Inc. (RCUS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +109. 7%, compared to -13. 7% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: EXEL returned +916. 7% versus RCUS's +52. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exelixis, Inc.

(EXEL) is the lower-risk stock at 0. 80β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 144% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exelixis, Inc.

(EXEL) is pulling ahead at 7. 0% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Exelixis, Inc. grew EPS 58. 0% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RCUS: 15.

4% to $30. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +916. 7% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXEL: +916. 7%, RCUS: +52. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RCUS is a small-cap quality compounder stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.